Search PubMed⌕ Search

Biomedical subjects

C Perret

Publications and source records attributed to C Perret.

At least 19 recordsLinked to original sources

Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas.

Perturbations to the Wnt signaling pathway have been implicated in a large proportion of human hepatocellular carcinomas (HCCs). Activating beta-catenin mutations and loss of function mutations in Axin1 are thought to be functionally equivalent. We examined the Wnt pathway in HCC by comparing the expression of beta-catenin target genes and the level of beta-catenin-dependent transcriptional activation, in 45 HCC tumors and four cell lines. Among these samples, beta-catenin and AXIN1 were mutated in 20 and seven cases, respectively. We found a significant correlation between activated beta-catenin mutations and overexpression of mRNA for the target genes glutamine synthetase (GS), G-protein-coupled receptor (GPR)49 and glutamate transporter (GLT)-1 (P=0.0001), but not for the genes ornithine aminotransferase, LECT2, c-myc and cyclin D1. We also showed that GS is a good immunohistochemical marker of beta-catenin activation in HCC. However, we observed no induction of GS, GPR49 or GLT-1 in the five inactivated Axin1 tumors. Beta-catenin-dependent transcriptional activation in two Axin1-mutated HCC cell lines was much weaker than in beta-catenin-mutated cell lines. Our results strongly suggest that in HCC, contrary to expectation, the loss of function of Axin1 is not equivalent to the gain of function of beta-catenin. Our results also suggest that the tumor suppressor function of Axin1 in HCC may be related to another, non-Wnt pathway.

Axin Protein↗

Overexpression of regenerating islet-derived 1 alpha and 3 alpha genes in human primary liver tumors with beta-catenin mutations.

The Wnt/beta-catenin signaling pathway is activated in many human hepatocellular carcinomas (HCC). We tried to identify the genes involved in carcinogenesis and progression of HCC with beta-catenin mutations. We used PCR-based subtractive hybridization to compare gene expression between malignant and benign components of a human HCC occurring in pre-existing adenoma activated for beta-catenin. Two of the genes identified belong to the Regenerating gene (REG) family. They encode the Regenerating islet-derived 3 alpha (REG3A/HIP/PAP/REG-III) and 1 alpha (REG1A) proteins, both involved in liver and pancreatic regeneration and proliferation. Using siRNA directed against beta-catenin, we demonstrated that REG3A is a target of beta-catenin signaling in Huh7 hepatoma cells. The upregulation of REG3A and REG1A expression is significantly correlated to the beta-catenin status in 42 HCC and 28 hepatoblastomas characterized for their beta-catenin status. Thus, we report strong evidence that both genes are downstream targets of the Wnt pathway during liver tumorigenesis.

Adenoma↗

Influence of creatine supplementation on 800 m wheelchair performance: a pilot study.

STUDY DESIGN: Double-blind, placebo-controlled, randomly assigned, crossover. OBJECTIVE: To assess the influence of a short-term oral creatine supplementation on 800 m wheelchair performance. SETTING: Swiss Paraplegic Centre, Nottwil, Switzerland. SUBJECTS: In total, six (four male, two female subjects) competitive wheelchair athletes participated in the study. Their age was 33.0+/-9.1 years, height 171.5+/-7.7 cm and weight 63.1+/-6.2 kg. Average weekly training volume was 10.0+/-3.7 h. All of them have been engaged in regular training for over 10.5+/-7.2 years. METHODS: During the two treatment periods, subjects ingested 4 x 5 g of creatine monohydrate or placebo (maltodextrin) daily during 6 days in a randomised order. A washout period of 4 weeks lay in-between the two supplementation periods. Before and after each treatment period athletes performed an all-out 800 m wheelchair test on a training roller. Time to complete 800 m, rate of perceived exertion (RPE), lactate concentrations and heart rate were measured. Before each test, body weight was determined. RESULTS: Times to complete 800 m before and after creatine supplementation (102.8+/-13.9 versus 100.5+/-11.3 s) compared to before and after placebo supplementation (101.6+/-15.6 versus 99.5+/-13.8 s) were not significantly different. Moreover, for all other parameters measured, no significant differences between creatine and placebo supplementation were found. CONCLUSION: A short-term oral creatine supplementation compared to placebo seems not to enhance performance over 800 m in trained, spinal cord-injured, wheelchair athletes.

Adult↗

Validation of a new portable ergospirometric device (Oxycon Mobile) during exercise.

The purpose of this study was to test the accuracy of a new portable spirometric-telemetric device (Oxycon Mobile) over a wide range of exercise intensities against an accurate stationary apparatus (Oxycon Pro). Therefore, fifteen endurance-trained subjects (VO2peak: 58.8 +/- 5.2 ml x min(-1) x kg(-1)) performed an incremental as well as an endurance exercise test on two different occasions. Gas exchange variables were measured by the two ergospirometric devices simultaneously. For this purpose, a special face mask was designed which allowed respiratory gas sampling with both devices at exactly the same time. Compared to the Oxycon Pro as an accurate reference system, the Oxycon Mobile showed significantly lower values for VO2 at 200 and 250 W during the incremental exercise test. For VCO2 no significant differences were found although the Oxycon Mobile seemed to systematically measure higher values. With regard to RER the Oxycon Mobile showed significantly higher values at all workloads tested. We therefore dissuade from comparing gas exchange variables collected by the Oxycon Mobile with data measured under laboratory conditions by an accurate reference system like the Oxycon Pro. Furthermore, the extrapolation of information about substrate utilization during different exercise durations and intensities from data measured by the Oxycon Mobile seems inappropriate.

Adult↗

Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent.

The BRCAPRO, Couch, Myriad I and II, Ontario Family History Assessment Tool (FHAT), and Manchester models have been used to predict BRCA1 or BRCA2 mutation carrier status of women at high risk for developing the heritable form of breast and ovarian cancers. We have evaluated these models for their accuracy in classifying 224 French Canadian families with at least three cases of breast cancer (diagnosed before the age of 65 years), ovarian cancer, or male breast cancer where mutation status was known for an index affected case used to assess the model. This series includes 44 BRCA1 and 52 BRCA2 mutation-positive families. Using receiver operator characteristics analyses, the C-statistics were found to be 0.81, 0.80, 0.79, and 0.74 for the BRCAPRO, FHAT, Manchester, and Myriad II models, respectively, when incorporating both BRCA1 and BRCA2 mutation carrier predictions. For the BRCAPRO model, 75% scored greater than a 0.43 probability in the mutation-positive group and 75% scored less than 0.50 in the mutation-negative group. Only 38 of 128 (30%) mutation-negative group had a probability greater than 0.43 with the BRCAPRO model. While all models were highly predictive of carrier status, the BRCAPRO model was the most accurate where a cut-off of 10% would have eliminated 60 of 128 (47%) mutation-negative families for genetic testing and only miss 10 of 96 (10%) mutation-positive families. A review of the cancer phenotypes with high BRCAPRO probabilities showed that significantly more metachronous bilateral breast cancer cases occurred in BRCA1/2 mutation carrier families in comparison to mutation-negative families, a feature which is not discriminated in the BRCAPRO model.

BRCA1 Protein↗

Influence of chronic supplementation of arginine aspartate in endurance athletes on performance and substrate metabolism - a randomized, double-blind, placebo-controlled study.

The intake of arginine aspartate has been shown to increase anabolic hormones like human growth hormone (hGH) and glucagon. The aim of our study was to investigate whether daily intake of two different dosages of arginine asparate during four weeks affects selected parameters of overtraining syndrome like performance, metabolic and endocrine parameters. Thirty male endurance-trained athletes were included in a randomized, double-blind, placebo-controlled study and divided into three groups. During four weeks, they ingested either arginine aspartate with a high concentration (H) of 5.7 g arginine and 8.7 g aspartate, with a low concentration (L) of 2.8 g arginine and 2.2 g aspartate or placebo (P).VO(2)peak and time to exhaustion were determined on a cycling ergometer in an incremental exercise test before and after supplementation. Before and after each incremental exercise test, concentrations of hGH, glucagon, testosterone, cortisol, ferritine, lactate, and urea were measured. Compared to placebo, no significant differences on endurance performance (VO(2)peak, time to exhaustion), endocrine (concentration of hGH, glucagon, cortisol, and testosterone) and metabolic parameters (concentration of lactate, ferritine, and urea) were found after chronic arginine aspartate supplementation. The chronic intake of arginine asparate during four weeks by male endurance athletes showed independent of dosage no influence on performance, selected metabolic or endocrine parameters. Consequently, there seems to be no apparent reason why the supplementation of arginine aspartate should be an effective ergogenic aid. The practice of using arginine aspartate as potential ergogenics should be critically reevaluated. Further investigations with higher dosage and extended supplementation periods should be performed.

Adult↗

Microsatellite variation and structure of 28 populations of the common wetland plant, Lychnis flos-cuculi L., in a fragmented landscape.

Habitat fragmentation is known to cause genetic differentiation between small populations of rare species and decrease genetic variation within such populations. However, common species with recently fragmented populations have rarely been studied in this context. We investigated genetic variation and its relationship to population size and geographical isolation of populations of the common plant species, Lychnis flos-cuculi L., in fragmented fen grasslands. We analysed 467 plants from 28 L. flos-cuculi populations of different sizes (60 000-54 000 flowering individuals) in northeastern Switzerland using seven polymorphic microsatellite loci. Genetic differentiation between populations is small (F(ST) = 0.022; amova; P < 0.001), suggesting that gene flow among populations is still high or that habitat fragmentation is too recent to result in pronounced differentiation. Observed heterozygosity (H(O) = 0.44) significantly deviates from Hardy-Weinberg equilibrium, and within-population inbreeding coefficient F(IS) is high (0.30-0.59), indicating a mixed mating breeding system with substantial inbreeding in L. flos-cuculi. Gene diversity is the only measure of genetic variation which decreased with decreasing population size (R = 0.42; P < 0.05). While our results do not indicate pronounced effects of habitat fragmentation on genetic variation in the still common L. flos-cuculi, the lower gene diversity of smaller populations suggests that the species is not entirely unaffected.

Altitude↗

Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas.

Although inappropriate activation of the Wnt/beta-catenin pathway has been implicated in the development of hepatocellular carcinoma (HCC), the role of this signaling in liver carcinogenesis remains unclear. To investigate this issue, we constructed a mutant mouse strain, Apc(lox/lox), in which exon 14 of the tumor-suppressor gene adenomatous polyposis coli (Apc) is flanked by loxP sequences. i.v. injection of adenovirus encoding Cre recombinase (AdCre) at high multiplicity [10(9) plaque-forming units (pfu) per mouse] inactivated the Apc gene in the liver and resulted in marked hepatomegaly, hepatocyte hyperplasia, and rapid mortality. beta-Catenin signaling activation was demonstrated by nuclear and cytoplasmic accumulation of beta-catenin in the hepatocytes and by the induction of beta-catenin target genes (glutamine synthetase, glutamate transporter 1, ornithine aminotransferase, and leukocyte cell-derived chemotaxin 2) in the liver. To test a long-term oncogenic effect, we inoculated mice with lower doses of AdCre (0.5 x 10(9) pfu per mouse), compatible with both survival and persistence of beta-catenin-activated cells. In these conditions, 67% of mice developed HCC. beta-Catenin signaling was strongly activated in these Apc-inactivated HCCs. The HCCs were well, moderately, or poorly differentiated. Indeed, their histological and molecular features mimicked human HCC. Thus, deletion of Apc in the liver provides a valuable model of human HCC, and, in this model, activation of the Wnt/beta-catenin pathway by invalidation of Apc is required for liver tumorigenesis.

Animals↗

[Interest of the criteria of Cochin to select patients with significant relief of low back pain after corticosteroid facet joint injections: a prospective study].

UNLABELLED: The seven Criteria of Cochin (CC), clinical descriptive criteria of low back pain (LBP), have been shown to be able to select patients whose LBP would respond well to facet joint anesthesia. AIM: To determine if these seven criteria set are able to select patients with significant relief of LBP after corticosteroid facet joint injections (CFJI). METHODS: Ninety-one patients with chronic LBP were included in a positive group (PG) or a negative group (NG) according to the number of the positive CC. Patients placed in the PG had five or more of the positive CC and those in the NG had less than five of the positive CC. All of them received CFJI on day 0 (D0). The severity of LBP and leg pain, disability and CFJI effect were evaluated on a self-questionnaire on D0, D2, D8 and D30. RESULTS: Two hundred and seventeen CFJI were performed (mean 2.1 per patient). Compared to the initial values we observed a significant reduction of the LBP at D2, D8 and D30 in both the groups (P < 0.05), a significant augmentation of the leg pain at D30 in the GN (P < 0.05) and a significant improvement of the Quebec back pain disability scale (QBDS) at D8 and D30 in the PG (P <0.05). Compared to the NG values, the PG had a significant higher global estimation of the efficacy of the treatment (P < 0.05) and a significant lesser intensive LBP (P <0.05) on D2, D8 and D30, a significant lesser intensive leg pain (P < 0.05) on D30, and a tendency to a more important reduction of the QBDS on D8 and D30 (P > 0.05). CONCLUSION: CC seems to be an effective test to select patients whose LBP would respond well to CFJI.

Adrenal Cortex Hormones↗

A new test to improve the training quality of wheelchair racing athletes.

STUDY DESIGN: Validation of a new wheelchair racing test. OBJECTIVE: To assess the reproducibility of test parameters at different, subjectively chosen, intensity levels in wheelchair racing athletes. SETTING: Swiss Paraplegic Centre, Nottwil, Switzerland. SUBJECTS: We tested 11 (eight male, three female) young competitive wheelchair racing athletes. Their age was 20.5+/-6.4 years, height 164.7+/-16.3 cm and weight 54.1+/-9.2 kg. Average weekly training time was 6.8+/-2.7 h. All had been engaged in regular training for over 3.9+/-2.8 years. METHODS: Within a period of 3+/-1 days, every athlete completed two identical tests in their own racing chair on a training roller. The tests consisted of five 1500 m bouts at routine training intensities of 1 (warm-up) up to 5 (race speed), with a rest of 2 min between each bout. The athletes were blinded to all the collected data during the whole of the test, except for indications of the 500, 1000 and 1500 m markers. We measured the overall time (for 1500 m), average speed, stroke frequency, heart rate, rate of perceived exertion (RPE) and the concentration of lactic acid for all five intensity bouts. In order to get a measure on how reproducible these intensity levels were, we compared the two tests of each athlete with each other, and calculated the root-mean-squared coefficients of variation (CV) for all measured parameters during every bout. RESULTS: CVs of the measured data show that the most reproducible values were found for bout 5 (2.6-7.9%); except for the lactic acid parameter. The heart rate (CV: 3.1-6.4%) and stroke frequency (CV: 6.5-7.9%) parameters reached rather constant values throughout all five bouts. Lactic acid concentrations showed very high CVs (16.8-29.7%). CONCLUSION: We conclude that this test is, with the exception of the lactic acid measurements, well reproducible, and particularly suitable for young wheelchair athletes. We find it to be a helpful tool for improving awareness for the individual training intensities, and for pursuing the development of the training process, as particularly the high-intensity bouts are well reproducible.

Adolescent↗

[The verrucous laryngeal carcinoma. A rare tumor with a difficult diagnosis].

OBJECTIVES: The authors report a single case of laryngeal verrucous carcinoma and review the literature. MATERIALS AND METHOD: The delay of the diagnosis, the difficulties in its establishment and the therapeutic methods are discussed in a review of the literature. RESULTS: Histopathological diagnosis remains difficult. This may explain a great number of mistakes and the subsequent delay of in treatment. The role of radiotherapy is discussed. CONCLUSION: The diagnosis and management of the laryngeal verrucous carcinoma is difficult.

Carcinoma, Verrucous↗

[The lymphoepithelial carcinoma of the parotid gland: a rare tumor for an European patient].

Lymphoepithelial carcinoma of the parotid is a rare and little known tumour The ethnic origin of the patients and the association with the Epstein-Barr virus are recognized but not invariable. The mechanism of the carcinogenesis thus remains an enigma. The authors report the observation of a patient which is remarkable because of his European origin and the positivity of serologies to the Epstein-Barr virus, and discuss the features of the lesion through the literature.

Carcinoma↗

Pharmacokinetics and absolute oral bioavailability of an 800-mg oral dose of telithromycin in healthy young and elderly volunteers.

BACKGROUND: This two-way, randomized, single-dose, crossover study determined the pharmacokinetics and absolute oral bioavailability of telithromycin in young and elderly healthy subjects. METHODS: Twelve young (18-40 years) and 12 elderly (>65 years and </=85 years) subjects received a single 800-mg oral dose of telithromycin or an intravenous infusion of 400 mg (young subjects) or 480 mg (elderly subjects) of telithromycin over 2.5 h in two treatment periods, separated by a 1-week washout period. The plasma concentrations and pharmacokinetic parameters of telithromycin and its major metabolite, RU 76363, were determined. Absolute oral bioavailability was calculated using the area under the plasma concentration-time curve (AUC) from zero hours to infinity. RESULTS: The absolute oral bioavailability of telithromycin was 57% in both young and elderly subjects. The AUC for the metabolite was lower after intravenous infusion of telithromycin, indicating first-pass loss following oral administration. Telithromycin was well tolerated in both groups of subjects. CONCLUSIONS: Telithromycin has an absolute oral bioavailability of 57% in young and elderly subjects and is well tolerated.

Administration, Oral↗

Early development of polycystic kidney disease in transgenic mice expressing an activated mutant of the beta-catenin gene.

Autosomal dominant polycystic kidney disease (ADPKD) is common and is a major cause of renal failure. Although the genetics of ADPKD are well known and have led to the discovery of polycystins, a new protein family, the pathogenesis of the disease remains largely unknown. Recent studies have indicated that the beta-catenin signaling pathway is one of the targets of the transduction pathway controlled by the polycystins. We have generated transgenic mice that overproduce an oncogenic form of beta-catenin in the epithelial cells of the kidney. These mice developed severe polycystic lesions soon after birth that affected the glomeruli, proximal, distal tubules and collecting ducts. The phenotype of these mice mimicked the human ADPKD phenotype. Cyst formation was associated with an increase in cell proliferation and apoptosis. The cell proliferation and apoptotic indexes was increased 4-5-fold and 3-4-fold, respectively, in cystic tubules of the transgenic mice compared to that of littermate controls. Our findings provide experimental genetic evidence that activation of the Wnt/beta-catenin signaling pathway causes polycystic kidney disease and support the view that dysregulation of the Wnt/beta-catenin signaling is involved in its pathogenesis.

Animals↗

Founder BRCA1 and BRCA2 mutations in early-onset French Canadian breast cancer cases unselected for family history.

Recently, founder BRCA1 and BRCA2 mutations were identified in Canadian breast cancer and breast-ovarian cancer families of French ancestry. The presence of a breast cancer case diagnosed at younger than 36 years of age was strongly predictive of the presence of any founder mutation screened. Here we report the occurrence of founder BRCA1 and BRCA2 mutations in a series of 61 French Canadian women with invasive breast cancer diagnosed at age 40 or younger, unselected for family history of breast and ovarian cancer. Germline mutations in BRCA1 (n = 4) and BRCA2 (n = 4) were identified in 8 of 61 (13%) cases. All BRCA1 mutations were found in invasive ductal carcinomas, the most common histologic type of tumor in this series. In contrast, the BRCA2 mutations were found in tumors of various histologic types: two ductal carcinomas, a tumor containing both ductal and lobular histologic types and an invasive lobular carcinoma. Of the 37 women with at least one first-, second- or third-degree relative with breast or ovarian cancer and the 24 women with no history of these cancers, 7 (19%) and 1 (4%), respectively, were mutation carriers. The seven mutation carriers with a family history of cancer had at least one first-, second- or third-degree relative with a breast cancer diagnosis at less than 51 years of age. The identification of founder BRCA1 and BRCA2 mutations in young-onset breast cancer cases unselected for family history can facilitate carrier detection when the expected yield of a comprehensive screen may be low.

Adult↗

Genetic susceptibility to breast cancer in French-Canadians: role of carcinogen-metabolizing enzymes and gene-environment interactions.

Breast cancer is the most frequent malignancy among women. Since genetic factors such as BRCA1 and BRCA2 as well as reproductive history constitute only 30% of the cause, environmental exposure may play a significant role in the development of breast cancer. Likewise, the relevant enzymes involved in the biotransformation of xenobiotics (from tobacco smoke, diet or other environmental sources) might play a role in breast carcinogenesis. Since individuals with modified ability to metabolize these carcinogens could have a different risk for breast cancer, we investigated the role of cytochromes P-450 (CYP1A1, CYP2D6), glutathione-S-transferases (GSTM1, GSTT1, GSTP1) and N-acetyltransferases (NAT1, NAT2) gene variants in breast carcinogenesis. A case-control study was conducted on 149 women with breast carcinoma and 207 healthy controls, both of French-Canadian origin. The CYP1A1*4 allele was found to be a significant risk determinant of breast carcinoma (OR = 3.3, 95% CI 1.1-9.7), particularly among post-menopausal women (OR = 4.0, 95% CI 1.2-13.8). The frequency of NAT2 rapid acetylators was increased among smokers (OR = 2.6, 95% CI 0.8-8.2), while the NAT1*10 allele conferred a 4-fold increase in risk among women who consumed well-done meat (OR = 4.4, 95% CI 1.0-18.9). These data suggest that CYP1A1*4, NAT1 and NAT2 variants are involved in the susceptibility to breast carcinoma by modifying the impact of exogenous and/or endogenous exposures.

Arylamine N-Acetyltransferase↗